Christian R Loehberg, Pamela L Strissel, Ralf Dittrich, Reiner Strick, Juergen Dittmer, Angela Dittmer, Ben Fabry, Willi A Kalender, Thorsten Koch, David L Wachter, Nicole Groh, Astrid Polier, Ina Brandt, Laura Lotz, Inge Hoffmann, Florentine Koppitz, Sonja Oeser, Andreas Mueller, Peter A Fasching, Michael P Lux, Matthias W Beckmann, Michael G Schrauder
PI3K/Akt/mTOR and p53 signaling pathways are frequently deregulated in tumors. The anticancer drug RAD001 (everolimus) is a known mTOR-inhibitor, but mTOR-inhibition leads to phosphorylation of Akt inducing resistance against RAD001 treatment. There is growing evidence that conflicting signals transduced by the oncogene Akt and the tumorsuppressor p53 are integrated via negative feedback between the two pathways. We previously showed that the anti-malarial Chloroquine, a 4-alkylamino substituted quinoline, is a p53 activator and reduced the incidence of breast tumors in animal models...
February 15, 2012: Biochemical Pharmacology